ProCE Banner Activity

Botensilimab ± Balstilimab for Refractory Microsatellite-Stable Metastatic Colorectal Cancer Without Liver Metastases

Conference Coverage
Slideset

An open-label, randomized phase II study showed an ORR benefit with the immune checkpoint inhibitor combination of botensilimab and balstilimab vs SoC treatment for refractory microsatellite-stable metastatic colorectal cancer without liver metastases.

Released: February 04, 2025

Expiration: August 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.

Boehringer Ingelheim Pharmaceuticals, Inc.

Exelixis, Inc.

Novartis Pharmaceuticals Corporation